Abstract
Hypogonadotrophic hypogonadism is a dysfunction characterized by the lack of gonadotrophin production and, therefore, attenuated or stopped gonadal action, which leads to anovulation and subsequent infertility. A new fixed combination of recombinant human FSH and recombinant human LH in a 2:1 ratio has recently been developed. Pharmacological studies show bioequivalence with the parameters of the separated compounds. Phase II/III studies have demonstrated high efficiency and safety for inducing ovulation in these patients. Studies analyzing the potential role of recombinant human luteinizing hormone supplement in normovulatory patients following ovarian stimulation for IVF–embryo transfer under pituitary downregulation, suggest a benefit in patients over 35 years old and/or with low response to stimulation with recombinant human follicle-stimulating hormone administered alone. However, further studies are needed to further analyze this issue.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.